Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial.
BACKGROUND The autoimmune disorder alopecia areata (AA) results in patchy or complete hair loss. OBJECTIVE To evaluate the efficacy and safety of the Janus kinase 1/2 inhibitor deuruxolitinib dosed 8 mg twice daily (BID) or 16 mg once daily (QD) in adults with severe AA. METHODS In this phase 2 study (NCT03811912),...